Bernstein Harold

MAZE President/R&D CMO Bernstein liquidates full position: 15,000 shares via 3 sales (Mar 20) for $736,439.29, blended $49.10/share.

Bernstein completed a complete liquidation of his 15,000-share stake at Maze Therapeutics via three separate sales on March 20, 2026, averaging $49.10 per share against a current price of $48.03. The filing is significant because a senior executive holding the President/R&D and Chief Medical Officer title has exited his entire equity position. The company is in a pre-revenue stage (latest quarterly revenue $0.00) with substantial net losses ($-30.1M), and Bernstein's full-position exit suggests a material reduction in his direct economic alignment with the company's future performance. The current price ($48.03) sits near the midpoint of his sale range ($48.20–$50.02), offering no obvious price-driven catalyst for the timing, though his cross-ticker sales history shows a prior average 30-day return of +4.4%, providing limited forward-looking signal.

MAZE President of R&D Harold Bernstein sells entire 30,000 share stake for $1,513,560.22 ($50.45 blended avg); zero holdings post-transaction.

Harold Bernstein, President of R&D & CMO at Maze Therapeutics, executed two separate sales totaling 30,000 shares for $1,513,560.22 on 2026-03-10, eliminating his entire equity position in the company. The stock currently trades at $51.84, only 2.7% above his blended average sale price of $50.45, placing the sales near recent highs (at the 52-week high). Maze is a pre-revenue clinical-stage biotech with a net loss of $30,087,000 for the latest quarter and a $2.5B market cap, typical of venture-backed therapeutics programs. Bernstein's prior transaction history at MAZE (5 recent trades, all sales in January and February 2026) shows mixed near-term outcomes (90-day data not yet measurable for most), but his cross-ticker track record of 7 prior sells averaged a +4.4% 30-day return, suggesting his sells have historically not been ill-timed in the immediate aftermath. Complete liquidation of an executive's holding is a notable event and warrants examination of whether it reflects material concerns about near-term prospects, though the timing relative to the company's stage and cash position requires context beyond the filing itself.

President of R&D sold entire 15,000-share MAZE position in 4 transactions on 2026-02-02, blended at $46.02, realizing $690,333.75.

Harold Bernstein, President of R&D & CMO, executed a complete exit of his MAZE holdings, liquidating 15,000 shares (100% of his pre-transaction position) across 4 separate sales on 2026-02-02, at prices ranging from $44.20 to $47.23 and a blended average of $46.02. The current stock price of $48.14 is at the 52-week high, and the stock has gained 24.6% over 30 days and 62.5% over 90 days, both substantial moves occurring after the filing date. His same-ticker history shows two prior sells on 2025-12-29 (both posted positive 30-day returns of 7.5% and 6.0%) and a sell on 2026-01-07, though outcomes on those trades remain unmeasurable. A 100% liquidation by a senior executive signals a definitive disengagement from the company at a time when the stock is trading near its highest valuation in 52 weeks, despite the company posting $0.00 in revenue and a net loss of $-30,087,000.00 in the latest quarter. This complete exit, combined with the absence of any offsetting purchases, merits investor attention given his operational role in research and development.

MAZE President & CMO Bernstein sells entire 25,156-share position for $1.0M at $40.20 on 2026-01-07; now holds zero shares

Harold Bernstein, President, R&D & CMO, executed a complete exit of his 25,156-share stake at $40.20, liquidating his entire position in Maze Therapeutics (pre-transaction: 25,156 shares; post-transaction: 0 shares, -100.0%). The transaction value of $1,011,298.87 occurred near the 52-week high of $42.60 (only -5.4% below peak), and follows two prior sales by the same insider at the identical ticker within the preceding week (both on 2025-12-29). Given that the company reports zero revenue in the latest quarter and negative net income of $-30,087,000.00, a full position exit by a senior R&D executive warrants scrutiny regarding confidence in near-term therapeutic progress and capital runway. The rapid succession of three sales across a single week, culminating in complete liquidation, reflects material action distinct from routine portfolio rebalancing.

MAZE President R&D/CMO Bernstein sells entire 45,000-share stake in 2 transactions for $1.8M at $40.34–$40.93

Bernstein, President of R&D and Chief Medical Officer, divested his complete 45.0K share position through 2 separate sales totaling $1,825,354.84 at blended average price of $40.56. The sale occurs as MAZE stock has appreciated 10.2% over 30 days and 56.3% over 90 days, yet the company continues to report no revenue and net losses of $-30,087,000.00, with a $2.0B market cap heavily dependent on pipeline value. The complete elimination of the R&D leader's holdings, particularly at current valuations near 52-week highs ($42.60), removes a key insider stake at a critical juncture for a clinical-stage biotech whose prospects depend entirely on unproven assets.